PK of GSK2982772 MR Formulations in Healthy Participants

Phase 1, open-label trial of GSK2982772 in inflammatory bowel disease (IBD), plaque psoriasis and rheumatoid arthritis (RA) (3 cohorts), sponsored by GSK. Primary endpoints: Area Under the Curve From Time Zero to Infinity at 32 hours, Area Under the Curve From Time Zero to Last Measurable Concentration at 32 hours and 4 more. Started Sep 2017; status: completed.